

Accessing treatments for hepatitis C through the Hepatitis C January 1, 1986 — July 1, 1990 Class Actions Settlement

What you need to know

What is hepatitis C?

Hepatitis is a medical word that describes when your liver is swollen, or inflamed. When this swelling is caused by the hepatitis C virus (HCV), the disease is called hepatitis C. It is also a “silent” disease. Often, you will not have symptoms until your liver is badly damaged.

Is hepatitis C common?

Yes. It is estimated that approximately 245,000 people in Canada are infected with the hepatitis C virus.

How does hepatitis C spread?

Hepatitis C is spread through blood-to-blood contact, which means that somehow blood infected with HCV gets into the bloodstream.

Can hepatitis C be cured?

Yes, hepatitis C can be cured. With recent advances in treatment, the chance to be cured is higher than ever before.

If you contracted HCV through tainted blood products between January 1, 1986 and June 30, 1990 and if you are an approved claimant of the Hepatitis C January 1, 1986 — July 1, 1990 Class Actions Settlement, you may qualify for access to therapies to treat hepatitis C.

What is the Hepatitis C January 1, 1986 — July 1, 1990 Class Actions Settlement?

The 1986-1990 Hepatitis C Settlement Agreement contains two plans:

■ Hemophiliac HCV Plan

This plan provides compensation to people who are hemophiliacs and persons with thalassemia major, who were infected with HCV through blood products received in Canada between January 1, 1986 and June 30, 1990 and certain members of their families.

■ Transfused HCV Plan

This plan provides compensation to people who were infected with HCV for the first time through a blood transfusion received in Canada between January 1, 1986 and June 30, 1990 and certain members of their families.

People who are approved claimants under the Hepatitis C January 1, 1986 — July 1, 1990 Class Actions Settlement may be reimbursed for their costs for treatments and generally accepted hepatitis C medications that are not recoverable under any public or private health care plan. Private insurance, an employee benefit package, a provincial health care plan or a provincial disability program may also cover these costs, in whole or in part. The Hepatitis C January 1, 1986 — July 1, 1990 Class Actions Settlement will reimburse any amount that is not covered by the aforementioned insurance or health plans.

What are the approval criteria to be eligible for the reimbursement of treatment costs incurred under the Hepatitis C January 1, 1986 — July 1, 1990 Class Actions Settlement?

Claimants for uninsured medical expenses such as drug therapy must meet all of the following criteria:

- Present a blood test that demonstrates that the HCV antibody is present in his/her blood;
- The treatment and/or medication is generally accepted by the medical community;
- The treatment and/or medication is proven to have been prescribed on the recommendation of one of the following medical specialists:
 - Gastroenterologist
 - Hematologist
 - Hepatologist
 - Oncologist
 - Internist
 - Nephrologist
- The treatment and/or medication was prescribed due to the HCV infection and not due to another medical condition;
- The costs that are claimed were/are not recoverable by or on behalf of the claimant under any public or private health care plan;
- Original receipts for all costs incurred or other evidence supporting the actual cost must be delivered to the Hepatitis C Claims Centre.

Learn more about the Hepatitis C January 1, 1986 — July 1, 1990 Class Actions Settlement

Visit www.hepc8690.ca to learn more about this class actions settlement. You may also contact the Administrator by calling 1-877-434-0944 or e-mailing info@hepc8690.ca.

Patient support programs offered by pharmaceutical companies

Many companies that make and sell hepatitis C medications have programs to support patients throughout treatment. Part of the support is helping them to determine whether or not they have access to medications and to help cover treatment costs.

Typically, these programs are designed to provide a wide range of customized services including reimbursement assistance, education and ongoing disease management support. They will not only support health care professionals but people living with hepatitis C throughout their treatment journey to achieve a possible cure. This assistance will cover the entire treatment regimen that your doctor will prescribe including drugs from one or more pharmaceutical companies.

The following patient support programs can help you and your health care provider determine if you qualify for treatment and medication cost reimbursement through the Hepatitis C January 1, 1986 – July 1, 1990 Class Actions Settlement. These programs offer assistance by providing drugs upfront to the 86-90 claimants through their specialty pharmacy. Once the 86-90 plan issues the reimbursement cheques to the patients for their treatment, they, in turn, must reimburse the pharmacy directly.

AbbVie Care™

Canadians prescribed Holkira™ Pak (paritaprevir/ritonavir/ombitasvir tablets; dasabuvir tablets) or Technivie™ (ombitasvir/paritaprevir/ritonavir tablets) will have the opportunity to request to be enrolled in AbbVie Care.

To enrol in the AbbVie Care Program, speak to your doctor or nurse or call 1-844-471-2273 for more information.

CLAIRE Patient Support Program

Canadians prescribed Daklinza™ (daclatasvir) will have the opportunity to request to be enrolled in the CLAIRE Patient Support Program.

To enrol in Bristol-Myers Squibb Canada's CLAIRE Patient Support Program, speak to your doctor or nurse. For more information about CLAIRE, call 1-844-428-2559.

Galexos™: BioAdvance® Patient Support Program

Canadians prescribed Galexos™ (simeprevir) will have the opportunity to request to be enrolled in the Galexos: BioAdvance Patient Support Program.

To enrol in Janssen's Galexos: BioAdvance Patient Support Program, speak to your doctor or nurse or call 1-855-512-3740 for more information.

Gilead Momentum HCV Support Program™

Canadians prescribed Sovaldi® (sofosbuvir) or Harvon® (ledipasvir and sofosbuvir in a single tablet) or Eplclusa™ (sofosbuvir and velpatasvir in a single tablet) will have the opportunity to request to be enrolled in the Gilead Momentum HCV Support Program.

To enrol in the Gilead Momentum HCV Support Program, speak to your doctor or nurse or call 1-855-447-7977 for more information.

Merck Care™ Hepatitis C Program

Canadians prescribed Zepatier™ (elbasvir and grazoprevir) will have the opportunity to request to be enrolled in the Merck Care Hepatitis C Program.

To enrol in the Merck Care Hepatitis C Program, speak to your doctor or nurse or you may call 1-866-872-5773, fax 1-866-949-9913 or e-mail merckcarehepc@innomar-strategies.com for more information.

Hepatitis C treatment is evolving. Talk to your doctor about a treatment plan that is right for you.

© July 2016, Canadian Hemophilia Society. All rights reserved.